Targetsite Therapeutics Corporation Profile last edited on: 8/15/22
CAGE: 8G8U0
UEI: HUAKPCHL21Q6
Business Identifier: Enhancing miRNA based drug development 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
300 George Street Suite 773g
New Haven, CT 06511
New Haven, CT 06511
| (203) 824-1517 |
| N/A |
| N/A |
Location: Single
Congr. District: 03
County: New Haven
Congr. District: 03
County: New Haven
Public Profile
Structured around harnessing the power of RNA-targeted oligonucleotides in therapeutics, and withthe principals having close ties to Yale, Targetsite Therapeutics Corporation is developing an miRNA target-based oligonucleotide platform for treatment of inflammatory disorders. Unique Opportunity: A novel target site blocker (TSB) oligonucleotide platform
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 1 | NIH | $245,000 | |
| Project Title: IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF) | ||||
| 2021 | 1 | NIH | $319,794 | |
| Project Title: IL-23 and IL-17A mRNA-targeted oligonucleotide therapeutics in autoimmune uveitis | ||||
Key People / Management
Jeffrey Bender -- Co-Founder
Vinod Satisch Ramgolam -- Associate Research Scientist and Co-Founder
Vinod Satisch Ramgolam -- Associate Research Scientist and Co-Founder
Company News
There are no news available.
